Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

804 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.
Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G. Regula JT, et al. Among authors: hartmann g. EMBO Mol Med. 2016 Nov 2;8(11):1265-1288. doi: 10.15252/emmm.201505889. Print 2016 Nov. EMBO Mol Med. 2016. PMID: 27742718 Free PMC article.
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.
Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Gemmy Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G. Regula JT, et al. Among authors: hartmann g. EMBO Mol Med. 2017 Jul;9(7):985. doi: 10.15252/emmm.201707895. EMBO Mol Med. 2017. PMID: 28533211 Free PMC article.
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.
Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Chui Ming GC, Tun SBB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G. Regula JT, et al. Among authors: hartmann g. EMBO Mol Med. 2019 May;11(5):e10666. doi: 10.15252/emmm.201910666. EMBO Mol Med. 2019. PMID: 31040127 Free PMC article.
LYSOPHOSPHATIDIC ACIDS AND AUTOTAXIN IN RETINAL VEIN OCCLUSION.
Dacheva I, Ullmer C, Ceglowska K, Nogoceke E, Hartmann G, Müller S, Rejdak R, Nowomiejska K, Reich M, Nobl M, Tandogan T, Kretz FT, Auffarth GU, Koss MJ. Dacheva I, et al. Among authors: hartmann g. Retina. 2016 Dec;36(12):2311-2318. doi: 10.1097/IAE.0000000000001112. Retina. 2016. PMID: 27648638
Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming.
Rupanagudi KV, Kulkarni OP, Lichtnekert J, Darisipudi MN, Mulay SR, Schott B, Gruner S, Haap W, Hartmann G, Anders HJ. Rupanagudi KV, et al. Among authors: hartmann g. Ann Rheum Dis. 2015 Feb;74(2):452-63. doi: 10.1136/annrheumdis-2013-203717. Epub 2013 Dec 3. Ann Rheum Dis. 2015. PMID: 24300027
Cathepsin S Cleavage of Protease-Activated Receptor-2 on Endothelial Cells Promotes Microvascular Diabetes Complications.
Kumar Vr S, Darisipudi MN, Steiger S, Devarapu SK, Tato M, Kukarni OP, Mulay SR, Thomasova D, Popper B, Demleitner J, Zuchtriegel G, Reichel C, Cohen CD, Lindenmeyer MT, Liapis H, Moll S, Reid E, Stitt AW, Schott B, Gruner S, Haap W, Ebeling M, Hartmann G, Anders HJ. Kumar Vr S, et al. Among authors: hartmann g. J Am Soc Nephrol. 2016 Jun;27(6):1635-49. doi: 10.1681/ASN.2015020208. Epub 2015 Nov 13. J Am Soc Nephrol. 2016. PMID: 26567242 Free PMC article.
804 results